We are live on ! Find out more
Blue Owl Capital Holdings

Blue Owl Capital Holdings Portfolio holdings

AUM $548M Turnover 33.33%
1-Year Est. Return 35.34%
This Fund
S&P 500
This Quarter Est. Return
-11.58%
1 Year Est. Return
+35.34%
3 Year Est. Return
+118.27%
5 Year Est. Return
+18.83%
10 Year Est. Return
–
AUM
$548M
AUM Growth
-$117M
Cap. Flow
+$26.5M
Cap. Flow %
4.83%
Top 10 Hldgs %
77.43%
Holding
93
New
17
Increased
8
Reduced
15
Closed
14
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
1.2 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
0.9 years

Top Sells

Rank Stock Value
1
SPCX icon
SpaceX
SPCX
+$65.8M
2
COF icon
Capital One
COF
+$24M
3
EYPT icon
EyePoint
EYPT
+$10.9M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$6.82M
5
DELL icon
Dell
DELL
+$6.4M

Sector Composition

Rank Sector Weight
1 Healthcare 57.1%
2 Industrials 26.97%
3 Financials 8.43%
4 Technology 4.56%
5 Consumer Discretionary 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SPCX icon
1
SpaceX
SPCX
$1.74T
$139M 25.43%
923,218
-475,597
-34% -$65.8M
2026 Q2
1 quarter
AKTS icon
2
Aktis Oncology
AKTS
$901M
$65.1M 11.89%
3,343,827
+273,608
+9% +$6.66M
2026 Q1
2 quarters
LTGO
3
Latigo Biotherapeutics
LTGO
$862M
$60.1M 10.97%
+3,596,780
New +$75.9M
2026 Q3
0 quarters
LRMR icon
4
Larimar Therapeutics
LRMR
$329M
$31.7M 5.79%
9,923,904
+760,747
+8% +$2.94M
2023 Q4
11 quarters
ETRA
5
Electra Therapeutics
ETRA
$510M
$29.4M 5.36%
+2,611,143
New +$32.1M
2026 Q3
0 quarters
NCDL icon
6
Nuveen Churchill Direct Lending
NCDL
$552M
$24.1M 4.4%
2,143,626
– –
2024 Q3
8 quarters
CGEM icon
7
Cullinan Therapeutics
CGEM
$577M
$21.5M 3.92%
1,399,899
-139,865
-9% -$2.68M
2023 Q4
11 quarters
OBDC icon
8
Blue Owl Capital
OBDC
$5.19B
$21.5M 3.92%
2,045,070
– –
2022 Q4
15 quarters
OBX icon
9
Obsidian Therapeutics
OBX
$741M
$20.4M 3.72%
+1,482,767
New +$29M
2026 Q3
0 quarters
SGMT icon
10
Sagimet Biosciences
SGMT
$648M
$11.1M 2.03%
1,125,544
-135,000
-11% -$1.24M
2023 Q4
11 quarters
DELL icon
11
Dell
DELL
$177B
$10.4M 1.9%
19,342
-13,619
-41% -$6.4M
2025 Q2
5 quarters
HLLY icon
12
Holley
HLLY
$279M
$10.3M 1.89%
4,376,888
– –
2024 Q3
8 quarters
CNDT icon
13
Conduent
CNDT
$136M
$7.86M 1.43%
5,036,595
– –
2024 Q3
8 quarters
FISN
14
Deep Fission
FISN
$171M
$6.84M 1.25%
1,333,333
– –
2026 Q2
1 quarter
AQST icon
15
Aquestive Therapeutics
AQST
$435M
$6.44M 1.18%
1,390,632
+447,700
+47% +$1.99M
2024 Q1
10 quarters
IMMX icon
16
Immix Biopharma
IMMX
$583M
$6.26M 1.14%
602,047
+164,495
+38% +$1.86M
2025 Q4
3 quarters
MPLT icon
17
MapLight Therapeutics
MPLT
$334M
$5.67M 1.04%
556,371
-173,558
-24% -$3.26M
2025 Q4
3 quarters
MANE icon
18
Veradermics
MANE
$5.04B
$5.46M 1%
+45,000
New +$4.92M
2026 Q3
0 quarters
IMA icon
19
ImageneBio
IMA
$48.8M
$5.2M 0.95%
1,135,081
+217,389
+24% +$1.18M
2023 Q4
11 quarters
IRD icon
20
Opus Genetics
IRD
$386M
$4.69M 0.86%
+969,605
New +$4.03M
2026 Q3
0 quarters
CRVS icon
21
Corvus Pharmaceuticals
CRVS
$816M
$4.13M 0.75%
358,600
-250,000
-41% -$3.48M
2026 Q1
2 quarters
RZLT icon
22
Rezolute
RZLT
$379M
$3.87M 0.71%
+935,000
New +$4.3M
2026 Q3
0 quarters
ARTV icon
23
Artiva Biotherapeutics
ARTV
$187M
$3.77M 0.69%
529,542
-345,000
-39% -$3.48M
2026 Q2
1 quarter
HELP icon
24
Helus Pharma
HELP
$488M
$3.54M 0.65%
288,282
+228,371
+381% +$2.39M
2026 Q2
1 quarter
QUIT icon
25
Achieve Life Sciences
QUIT
$612M
$3.34M 0.61%
+412,654
New +$2.95M
2026 Q3
0 quarters

Similar funds

Blue Owl Capital Holdings's Q3 2026 Portfolio in Review

As of Q3 2026, Blue Owl Capital Holdings held 93 positions worth $548M, down 18% from $665M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Blue Owl Capital Holdings deployed $26.5M of net new capital in Q3 2026, opening 17 new positions and adding to 8 existing holdings. Its largest new stake was Latigo Biotherapeutics: 3,596,780 shares worth $60.1M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 44% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was SpaceX, an estimated $65.8M trimmed.

  • Blue Owl Capital Holdings's largest Q3 2026 buy was Latigo Biotherapeutics: 3,596,780 shares worth $60.1M.
  • Blue Owl Capital Holdings added most to Aktis Oncology in Q3 2026, an estimated $6.66M increase.
  • Blue Owl Capital Holdings's biggest Q3 2026 reduction was SpaceX, cutting an estimated $65.8M.
  • Blue Owl Capital Holdings fully exited Capital One in Q3 2026, selling an estimated $24M.
  • Blue Owl Capital Holdings's ten largest holdings make up 77% of its $548M portfolio in Q3 2026.
  • Blue Owl Capital Holdings opened 17 new positions and closed 14 in Q3 2026.
  • Blue Owl Capital Holdings's portfolio value fell 18% quarter-over-quarter to $548M.

Based on Blue Owl Capital Holdings's 13F filing for Q3 2026, filed 13 Nov 2026.